DNA Labs UAE is at the forefront of genetic testing, offering a comprehensive range of services designed to provide insights into various genetic conditions. One such condition that DNA Labs UAE can help diagnose is Primary Ciliary Dyskinesia (PCD), specifically Type 13, which is linked to mutations in the DNAAF1 gene. Understanding the symptoms of this condition is crucial for early diagnosis and management. This article will delve into the symptoms associated with DNAAF1 Gene Primary Ciliary Dyskinesia Type 13, the importance of genetic testing, and details regarding the test available at DNA Labs UAE, including its cost.
Symptoms of DNAAF1 Gene Primary Ciliary Dyskinesia Type 13
Primary Ciliary Dyskinesia (PCD) Type 13 is a rare genetic disorder caused by mutations in the DNAAF1 gene. This condition affects the function of cilia, which are microscopic, hair-like structures that line the airways, reproductive system, and other parts of the body. The impaired function of cilia leads to a range of symptoms, primarily affecting respiratory function. Notable symptoms include:
- Chronic respiratory infections starting from a young age, leading to conditions such as bronchitis and pneumonia.
- Situs inversus in some patients, a condition where the major visceral organs are reversed or mirrored from their normal positions.
- Difficulty clearing mucus from the airways, resulting in a persistent cough.
- Ear infections, which can sometimes lead to hearing loss.
- Infertility issues due to affected motility of sperm in males and possibly affected fallopian tube function in females.
Recognizing these symptoms early can lead to a timely diagnosis, which is essential for managing the condition and improving the quality of life for those affected.
The Importance of Genetic Testing for DNAAF1 Gene Primary Ciliary Dyskinesia Type 13
Genetic testing plays a pivotal role in diagnosing DNAAF1 Gene Primary Ciliary Dyskinesia Type 13. Through genetic testing, mutations in the DNAAF1 gene can be identified, confirming the diagnosis and allowing for targeted management strategies. It also provides valuable information for family planning, as PCD Type 13 is inherited in an autosomal recessive manner, meaning that both parents must carry a copy of the mutated gene to pass the condition onto their children.
DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 Genetic Test at DNA Labs UAE
DNA Labs UAE offers a specialized genetic test for DNAAF1 Gene Primary Ciliary Dyskinesia Type 13. This test is designed to detect mutations in the DNAAF1 gene, providing a definitive diagnosis for affected individuals. The cost of the test is 4400 AED, an investment in understanding and managing this condition effectively.
For more information about the DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 Genetic Test, including how to order the test, please visit DNA Labs UAE.
Early diagnosis through genetic testing can significantly impact the management of Primary Ciliary Dyskinesia Type 13, leading to improved outcomes and a better quality of life. If you or a loved one is experiencing symptoms associated with this condition, consider reaching out to DNA Labs UAE to discuss genetic testing options.
